Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

To develop, manufacture, and commercialize innovative and cost-effective pharmaceutical products to improve patients' quality of life.

Our vision is to become the leading specialty pharmaceutical company in the world, and to create innovative, cost-effective solutions that improve the lives of our patients.

Citius has been recognized for its innovative approach to drug development. The company has been awarded numerous awards and accolades, including a 2011 Buzz of BIO Award, a 2012 Top 50 Drug Delivery Idea of 2012 Award, and a 2013 Frost & Sullivan Company of the Year Award.